TY - JOUR
T1 - Lipid based intramuscular long-acting injectables: Current state of the art
AU - Wilkinson, Janine
AU - Ajulo, Damilola
AU - Tamburrini, Valeria
AU - Le Gall, Gwenaelle
AU - Kimpe, Kristof
AU - Holm, Rene
AU - Belton, Peter
AU - Qi, Sheng
N1 - Acknowledgement: The authors D. Ajulo and V. Tamburriniwould like to thank the funding from the Flemish funding agency VLAIO and Janssen Pharmaceuticals for supporting their PhD studies.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Long acting injectables (LAI) have received increased research and commercial interest due to their potential for improving treatment effectiveness and adherence for antipsychotic, antiviral and addiction treatments. A range of materials have been used to formulate LAI products, including lipids and polymers. Classic lipid-based LAI, such as oil solutions of antipsychotic drugs, have been widely prescribed to patients. Clinical evidence has shown significantly improved key therapeutic markers such as reduction of relapses in the case of schizophrenia patients. The commercial LAI products can be given either via subcutaneous or intramuscular injection. The main types of lipid-based LAI formulations include oil solutions, lipid-based nanoparticles and lipid based liquid crystal formulations, which are currently clinically available, and oil suspensions and oleogels and which currently have no commercial products available. This review will discuss all relevant aspects related to the development of lipid-based long acting injectables with a special focus on intramuscular (IM) injectables. It aims to provide useful guidance on effective future LAI product design and development. Lipid-based nanoformulations are not discussed in this review as they are thoroughly reviewed in literature elsewhere.
AB - Long acting injectables (LAI) have received increased research and commercial interest due to their potential for improving treatment effectiveness and adherence for antipsychotic, antiviral and addiction treatments. A range of materials have been used to formulate LAI products, including lipids and polymers. Classic lipid-based LAI, such as oil solutions of antipsychotic drugs, have been widely prescribed to patients. Clinical evidence has shown significantly improved key therapeutic markers such as reduction of relapses in the case of schizophrenia patients. The commercial LAI products can be given either via subcutaneous or intramuscular injection. The main types of lipid-based LAI formulations include oil solutions, lipid-based nanoparticles and lipid based liquid crystal formulations, which are currently clinically available, and oil suspensions and oleogels and which currently have no commercial products available. This review will discuss all relevant aspects related to the development of lipid-based long acting injectables with a special focus on intramuscular (IM) injectables. It aims to provide useful guidance on effective future LAI product design and development. Lipid-based nanoformulations are not discussed in this review as they are thoroughly reviewed in literature elsewhere.
KW - Intramuscular
KW - Lipid based liquid crystals
KW - Lipid-based formulations
KW - Long-acting injectables
KW - Oil solutions
KW - Oleogels
UR - http://www.scopus.com/inward/record.url?scp=85137643220&partnerID=8YFLogxK
U2 - 10.1016/j.ejps.2022.106253
DO - 10.1016/j.ejps.2022.106253
M3 - Article
VL - 178
JO - European Journal of Pharmaceutical Sciences
JF - European Journal of Pharmaceutical Sciences
SN - 0928-0987
M1 - 106253
ER -